Change in bone mineral density is predictive for fracture risk reduction with ibandronate: Further insights from a phase III study of intravenous ibandronate injection.

被引：0
|
作者：
Miller, PD
Epstein, S
Huss, H
Wilson, KM
Schimmer, RC
Wasnich, R
机构：
[1] Colorado Ctr Bone Res, Lakewood, CO USA
[2] Mt Sinai Med Ctr, New York, NY USA
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Radiant Res, Honolulu, HI USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S310 / S310
页数：1
相关论文
共 50 条
  • [1] Association between fracture efficacy and bone mineral density change with ibandronate: Results from the bone study
    Wasnich, R
    Miller, PD
    Huss, H
    Chesnut, CH
    Wilson, K
    Schimmer, RC
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S76 - S76
  • [2] Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
    Hiroshi Hagino
    Seitaro Yoshida
    Junko Hashimoto
    Masayuki Matsunaga
    Masato Tobinai
    Toshitaka Nakamura
    [J]. Calcified Tissue International, 2014, 95 : 557 - 563
  • [3] Relationship between annual cumulative exposure to ibandronate, bone mineral density and clinical fracture reduction
    Sebba, A.
    Barr, C.
    Harris, S.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S247 - S247
  • [4] Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
    Hagino, Hiroshi
    Yoshida, Seitaro
    Hashimoto, Junko
    Matsunaga, Masayuki
    Tobinai, Masato
    Nakamura, Toshitaka
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2014, 95 (06) : 557 - 563
  • [5] Consistent bone mineral density gains with intravenous ibandronate injections: Results from the DIVA study.
    Emkey, R
    Halse, J
    Kruse, HP
    Hughes, C
    Ward, P
    Masanauskaite, D
    Recker, RR
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S285 - S285
  • [6] BONE MINERAL DENSITY INCREASES WITH MONTHLY IV IBANDRONATE INJECTIONS CONTRIBUTE TO ITS FRACTURE RISK REDUCTION IN PRIMARY OSTEOPOROSIS: 3-YEAR ANALYSIS OF THE PHASE III MOVER STUDY
    Hagino, H.
    Nakamura, T.
    Ito, M.
    Nakano, T.
    Hashimoto, J.
    Tobinai, M.
    Mizunuma, H.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S592 - S593
  • [7] Significant reduction in vertebral fracture risk: Evidence for the efficacy of daily and intermittent ibandronate from a large phase III study
    Christiansen, C
    Chesnut, CH
    Delmas, PD
    Skag, A
    Recker, RR
    Stakkestad, JA
    Hoiseth, A
    Felsenberg, D
    Gilbride, J
    Schimmer, RC
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 94 - 95
  • [8] Is bone mineral density predictive of fracture risk reduction?
    Cefalu, CA
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (03) : 341 - 349
  • [9] Benefits of oral ibandronate on non-vertebral fracture risk in postmenopausal osteoporosis: Further analyses from a pivotal phase III study
    Emkey, R.
    Chesnut, C. H.
    Schimmer, R. C.
    Neate, C.
    Recker, R. R.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S329 - S329
  • [10] The DIVA study: Substantial hip bone mineral density improvements with intermittent intravenous ibandronate injections.
    Lewiecki, E.
    Adami, S.
    Bianchi, G.
    Sambrook, P.
    Hughes, C.
    Mairon, N.
    Jonkanski, I.
    Bolognese, M.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S70 - S70
12345